Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation

Launched by MSD ITALIA S.R.L. · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how Cytomegalovirus (CMV) can reactivate in children after they have received a special type of treatment called allogeneic hematopoietic stem cell transplantation (HSCT). This treatment is often used for various blood disorders and cancers. Researchers want to gather important information about how CMV affects these young patients, both in terms of their health and the costs associated with their care. The goal is to help doctors and healthcare providers better manage CMV infections in children undergoing this procedure.

To participate in this study, patients must be between birth and 17 years old at the time they received their HSCT, and they must have had the transplant between January 2018 and June 2020. A parent or guardian must also agree to the study by signing a consent form. It's important to note that children who have received a medication called Letermovir at any time are not eligible to join the study. Since the trial is currently not recruiting participants, families interested in this research will need to wait until it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT);
• • Patients who received allogeneic HSCT between January 2018 and June 2020;
• • Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable.
• Exclusion Criteria:
• • Letermovir use at any time